부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
R&D news | Bukwang initiates phase 3 study with lurasidone HCl for pat..
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced on April 9, 2018 that it ..
2018.04.09
R&D news | Listening to shareholders’ opinions and answering to inquiri..
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced that all of the seven res..
2018.03.19
R&D news | Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered pate..
Bukwang said it registered patents on the use and composition of ‘JM-010’ with K..
2018.01.31
R&D news | Bukwang Pharmaceutical Co., Ltd. a novel candidate for type..
Bukwang Pharmaceutical Co., Ltd. announced on today that global phase 2b study o..
2018.01.26
R&D news | Acer Therapeutics, in which Bukwang is investing, is to go p..
Acer Therapeutics Inc. (“Acer”), an ultra orphan drug development company in whi..
2017.07.04
R&D news | Bukwang announces the conclusion of an exclusive license agr..
Bukwang Pharmaceutical Co., Ltd. (“Bukwang”) announced today that the company ha..
2017.04.19
6
7
8